TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-small cell lung cancer (NSCLC).

OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease with broad-reaching impact on public health, accounting for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In the year 2018, it is estimated that approximately 234,030 individuals will be diagnosed and more than 154,000 will die from the disease. Today, however, many have renewed optimism that these trends have already started to change as recent research advances have led to an explosion in lung cancer genetic and biologic knowledge among scientists and clinicians working in this area of cancer medicine. Consequently, NSCLC currently represents one of the most rapidly evolving fields in oncology, as evidenced by a multitude of recent FDA approvals and the emergence of many pivotal data sets and novel agents potentially poised to disrupt traditional management algorithms.

Although medical oncologists have been routinely responsible for counseling patients with regard to therapeutic decision-making, oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being. These video proceedings from the fourth part of a 6-part integrated CNE curriculum originally held at the 2018 ONS Annual Congress feature discussions with leading lung cancer investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with NSCLC.

LEARNING OBJECTIVES
• Appreciate available research data documenting the benefits and risks of sequential anti-PD-L1 antibody therapy for patients with locally advanced, unresectable NSCLC.
• Use biomarkers, clinical characteristics and tumor histology to select individualized front-line and subsequent treatment approaches for patients with metastatic NSCLC.
• Discuss the benefits and risks associated with evidence-based systemic treatments for metastatic NSCLC, including chemotherapeutic agents, targeted biologic therapies and immunotherapies.
• Educate patients about the side effects associated with existing and recently approved therapies, and provide preventive strategies to reduce or ameliorate these toxicities.
• Assess emerging research on the benefits of early palliative care for patients with metastatic NSCLC, and integrate this information, as appropriate, into patient consultations.
• Recall ongoing trials of other investigational approaches and agents in NSCLC, and refer patients and obtain consent for study participation.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENTS
This educational activity for 2.8 contact hours is provided by RTP during the period of July 2018 through July 2019.
This activity is awarded 2.8 ANCC pharmacotherapeutic contact hours.

ONCOLOGY NURSING CERTIFICATION CORPORATION (ONCC)/INDIVIDUAL LEARNING NEEDS ASSESSMENT (ILNA) CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. To review certification qualifications, please visit ResearchToPractice.com/ONS2018/ILNA.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

FOR SUCCESSFUL COMPLETION

This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSLung2018/CNE.

CONTENT VALIDATION AND DISCLOSURES

RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Julie R Brahmer, MD**
Director, Thoracic Oncology Program
Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview
Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, Maryland

**Advisory Committee:** Amgen Inc, Bristol-Myers Squibb Company, Merck; **Consulting Agreements:** Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck; **Contracted Research:** AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company.

**Jennifer Kapo, MD**
Chief, Palliative Care Service
Yale New Haven Hospital
Associate Professor of Medicine
Department of Internal Medicine
Yale University School of Medicine
New Haven, Connecticut

No relevant conflicts of interest to disclose.

**Judy Pagtama, RN, MSN, FNP-C**
Nurse Practitioner
Stanford Cancer Institute
Palo Alto, California

No relevant conflicts of interest to disclose.

**Gregory J Riely, MD, PhD**
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

**Contracted Research:** Genentech, Pfizer Inc, Takeda Oncology;
**Paid Travel:** Merck; **Other:** AstraZeneca Pharmaceuticals LP.

**Elizabeth S Waxman, RN, MSN, ANP-BC**
Nurse Practitioner in the Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

No relevant conflicts of interest to disclose.


**RESEARCH TO PRACTICE CME/CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS** — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, Merck and Takeda Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: July 2018
Expiration date: July 2019

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.
Select Publications


Gandhi L et al. KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC. *Proc AACR* 2018;Abstract CT075.


Hellmann MD et al. Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small-cell lung cancer (NSCLC): Initial results from CheckMate 227. *Proc AACR* 2018;Abstract CT077.


Kowanetz M et al. IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups. *Proc AACR* 2018;Abstract CT076.


Ou S-HI et al. Intracranial efficacy of brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases. *Proc ASCO* 2017;Abstract 2006.


Special Session: Jennifer Kapo, MD


